Health
Ipsen Pulls Cancer Drug Tazverik Over Secondary Cancer Risk
Ipsen is withdrawing Tazverik from the market after a monitoring committee found cases of secondary blood cancers in a confirmatory trial.
Key Takeaways
- Data monitoring committee found secondary blood cancers in confirmatory trial patients
- Tazverik was approved under accelerated pathway for rare epithelioid sarcoma
- Withdrawal raises questions about long-term safety of EZH2 inhibitor drug class
DE
DT Editorial AI··via endpoints.news